The DESTINY-Breast04 trial spotlighted the superior efficacy of HER2-targeted antibody-drug conjugates (ADCs) compared to standard chemotherapy options in patients with HER2-low advanced breast cancer (6). This evidence concerns the gene ERBB2 and breast carcinoma.